Viral Vectors
CUSTOMER CHALLENGE
Viral vectors can be used for a range of applications, from direct in vivo gene delivery in genetic therapies, to in vitro transduction for gene modified cell therapies such as CAR-T, as well as oncolytic applications. Manufacturing the virus is almost always highly complex, involving critical input materials such as plasmids, meaning there are much higher production costs than traditional biopharmaceuticals.
Traditional testing approaches often do not provide the requisite detail of information that the regulators require. Combined with widespread compatibility and volume requirement issues, customers must find alternative testing and release strategies for these incredible new modalities.
PATHOQUEST SOLUTION
PathoQuest can help characterize, QC and release your viral vectors across the manufacturing journey
DISCOVERY
PRE-CLINICAL
PHASE 1
PHASE 2
PHASE 3
MARKET
Cell line selection
Viral seed selection
Cell line characterization – MCB, WCB, End of Production
Viral seed stock characterization
In-process testing – bulk harvest lot release, biosafety and viral testing
Final product release testing
Monitoring – on/off target integration, replication competency
Plasmid identity testing and raw material screening
Investigatory support
PATHOQUEST SOLUTION
PathoQuest can help characterize, QC and release your viral vectors across the manufacturing journey
OUR EXPERTISE
PathoQuest has been working with many leading global innovators to help them address the unique challenges that viral vectors present. By using our expert GMP NGS services, our clients have been able to overcome compatibility issues with traditional cell or animal-based testing and characterization, enabling them to deliver life-changing therapies to patients.
PathoQuest actively participates in regulatory and expert industry interest groups, associations and consortia, as well as frequently publishing in peer-reviewed journals. We lead the way in both innovation and acceptance of NGS technology, especially when applied to the specific challenges of viral vector QC.
CHALLENGES SOLVED
PathoQuest addresses the key challenges you face in manufacturing and releasing your viral vector by addressing key concerns:
- Faster cell line development and clone selection with deeper genetic insights
- De-risking your manufacturing process by rapidly screening critical raw materials such as serum and plasmids
- Reducing the cell line and plasmid characterization bottleneck, allowing you to get your therapy into clinic faster
- Detection of sequence variation to low levels, ensuring the highest possible quality and safety
- Addressing key concerns with viral vector testing by reducing volume requirements and cell-based assay compatibility issues
- Providing additional assurance of biosafety where processes such as viral clearance can be challenging
- Meeting corporate 3Rs ethical objectives by removing animal models
Modalities
mAbs and Recombinants
Bacterial and mammalian produced proteins, hormones and peptides
READ MORE
Viral Vectors
Viral gene delivery, oncolytic and immunotherapy including manufacturing plasmids
READ MORE
Cell Therapies
Including gene modified, or unmodified stem cell therapies, allogeneic or autologous
READ MORE
Vaccines
Inactivated, live-attenuated, recombinant, RNA and viral vector products
READ MORE
RNA
Immunotherapies, antiviral, vaccines, RNAi and CRISPR based gene editing
READ MORE
Cultivated Meat
Engineered cells and tissues cultured in more ethical in vitro environments
READ MORE
Contact us
U.S.
466 Devon Park Dr
Wayne, PA 19087
United States
E: contact@pathoquest.com
Sign up for our latest news
France
+33 (0)1 70 82 17 90
Biopark -Bâtiment B,
11, rue Watt
75013 Paris, France
How can PathoQuest help?
U.S.
466 Devon Park Dr
Wayne, PA 19087
United States
France
+33 (0)1 70 82 17 90
Biopark -Bâtiment B,
11, rue Watt
75013 Paris, France
E: contact@pathoquest.com
How can PathoQuest help?
Sign up for our latest news